Aspira Pathlab & Diagnostics Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Aspira Pathlab & Diagnostics Ltd. on BSE

Load latest

Aspira Pathlab & Diagnostics Ltd.

09 Apr 2024, 11:40AM

62.70

0.02%

Corp. Note

Aspira Pathlab & Diagnostics Ltd - 540788 - Format of the Annual Disclosure to be made …

BSE India

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Aspira Pathlab & Diagnostics Ltd 2 CIN NO. L85100MH1973PLC289209 3 Report filed for FY 2023-2024 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2023-2024,2024-2025 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2022-2023,2023-2024 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Krupali ShahDesignation :-Company Secretary Name of the Chief Financial Officer :- Balkrishna Talawadekar Designation : -Chief Financial Officer Date: 09/04/2024

pdf

Aspira Pathlab & Diagnostics Ltd.

09 Apr 2024, 10:54AM

62.70

0.02%

Corp. Note

Aspira Pathlab & Diagnostics Ltd - 540788 - Format of the Initial Disclosure to be made …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyAspira Pathlab & Diagnostics Ltd 2CIN NO.L85100MH1973PLC289209 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Krupali Shah Designation: Company Secretary EmailId: krupali.shah@aspiradiagnostics.com Name of the Chief Financial Officer: Balkrishna Talawadekar Designation: Chief Financial Officer EmailId: balkrishna.talawadekar@aspiradiagnostics.com Date: 09/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Aspira Pathlab & Diagnostics Ltd.

04 Apr 2024

62.70

0.02%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) …

BSE India

Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2024

pdf

Aspira Pathlab & Diagnostics Ltd.

04 Apr 2024

62.70

0.02%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Intimation Under Regulation 30 Of The SEBI(LODR)Regulations, 2015-Incorporation …

BSE India

We wish to inform that the Company along with two other Designated Partners has incorporated Limited Liability Partnership namely "Aspira DNA Diagnostics Gujarat LLP" on April 02, 2024.

pdf

Aspira Pathlab & Diagnostics Ltd.

02 Apr 2024

62.70

0.02%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Intimation Under Regulation 30 Of SEBI(LODR)Regulation, 2015-Incorporation Of …

BSE India

We wish to inform that the Company along with two other Designated Partners has incorporated Limited Liability Partnership namely "Aspira DNA Diagnostics Gujarat LLP" on April 02, 2024 under LLPIN: ACG-3843

pdf

Aspira Pathlab & Diagnostics Ltd.

01 Apr 2024

62.70

0.02%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Inauguration Of A Two New Diagnostics Centers Today …

BSE India

Two new Diagnostics Centers namely Ashirvad Pathology Laboratory in Nashik and Shobha Diagnostics Center in Malad has been inaugurated today.

pdf

Aspira Pathlab & Diagnostics Ltd.

29 Mar 2024

62.70

0.02%

SAST

Aspira Pathlab & Diagnostics Ltd - 540788 - Closure of Trading Window

BSE India

Closure of Trading Window for the Designated Persons for the quarter & year ended March 31, 2024.

pdf

Aspira Pathlab & Diagnostics Ltd.

28 Mar 2024

62.70

0.02%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Code of Conduct under …

BSE India

Enclosed herewith disclosure in Form C received from Mr.Jay Arvind Bhanushali, Promoters Immediate Relative of the Company for the acquisition of shares from the market.

pdf

Aspira Pathlab & Diagnostics Ltd.

22 Mar 2024

62.70

0.02%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Code of Conduct under …

BSE India

Enclosed herewith disclosure in Form C received from Mr. Jay Arvind Bhanushali,Promoters Immediate Relative of the Company for the acquisition of shares from the market.

pdf

Aspira Pathlab & Diagnostics Ltd.

21 Mar 2024

62.70

0.02%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Code of Conduct under …

BSE India

Enclosed herewith disclosure in Form C received from Mr. Nikunj Velji Mange, Executive Director (08489442) of the Company for the acquisition of shares from the market.

pdf

Is Aspira Pathlab & Diagnostics Ltd. worth buying?

4 Votes:

Buy 25.0%

Sell 50.0%

Hold 25.0%